Reliv' International (RELV) Competitors

Reliv' International (NASDAQ:RELV) and iBio (NYSE:IBIO) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Which has more volatility & risk, RELV or IBIO?

Reliv' International has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500. Comparatively, iBio has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Which has better earnings and valuation, RELV or IBIO?

Reliv' International has higher revenue and earnings than iBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reliv' International	$35.06M	0.13	-$440K	N/A	N/A
iBio	$400K	45.22	-$24.91M	-$1.74	-0.51

Do institutionals and insiders hold more shares of RELV or IBIO?

8.0% of Reliv' International shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 31.2% of Reliv' International shares are held by insiders. Comparatively, 2.8% of iBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the media refer more to RELV or IBIO?

In the previous week, iBio had 4 more articles in the media than Reliv' International. MarketBeat recorded 4 mentions for iBio and 0 mentions for Reliv' International. Reliv' International's average media sentiment score of 0.00 equaled iBio'saverage media sentiment score.

Company	Overall Sentiment
Reliv' International	Neutral
iBio	Neutral

Is RELV or IBIO more profitable?

iBio has a net margin of 0.00% compared to Reliv' International's net margin of -0.61%. Reliv' International's return on equity of -1.89% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reliv' International	-0.61%	-1.89%	-1.31%
iBio	N/A	-73.15%	-45.51%

Do analysts prefer RELV or IBIO?

iBio has a consensus target price of $3.50, suggesting a potential upside of 291.94%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Reliv' International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reliv' International	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
iBio	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

iBio beats Reliv' International on 8 of the 14 factors compared between the two stocks.